	US 12,280,104 B2
	Composition and methods for MRNA vaccines against novel omicron coronavirus infections
David Brown, Gaithersburg, MD (US); Yong-Sik Bong, Frederick, MD (US); Neeti Ananthaswamy, Potomac, MD (US); Naihsuan C. Guy, Gaithersburg, MD (US); and Dong Shen, Baltimore, MD (US)
Assigned to RNAIMMUNE, INC., Gaithersburg, MD (US)
Filed by RNAimmune, Inc., Gaithersburg, MD (US)
Filed on Oct. 31, 2023, as Appl. No. 18/385,879.
Claims priority of provisional application 63/381,901, filed on Nov. 1, 2022.
Prior Publication US 2024/0156947 A1, May 16, 2024
Int. Cl. A61K 39/215 (2006.01); A61K 9/51 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61K 9/5123 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/6031 (2013.01)]

30 Claims

1. A ribonucleic acid (RNA) encoding a spike(S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the S protein or immunogenic fragment thereof comprises the polypeptide of SEQ ID NO: 55.